| scholarly article | Q13442814 |
| P50 | author | Renato Franco | Q37376215 |
| Daniele Santini | Q37837892 | ||
| Michele Caraglia | Q38321049 | ||
| Claudio Arra | Q39050534 | ||
| Alfredo Budillon | Q40122753 | ||
| Elena Di Gennaro | Q57061563 | ||
| Alessandra Leone | Q57629449 | ||
| Antonio Luciano | Q59674725 | ||
| Francesca Bruzzese | Q63737239 | ||
| Maria Rita Milone | Q63737317 | ||
| Chiara Ciardiello | Q86584762 | ||
| P2093 | author name string | B Pucci | |
| M Rocco | |||
| M I Chianese | |||
| P2860 | cites work | The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment | Q24537306 |
| The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species | Q28349324 | ||
| p38 MAP-kinases pathway regulation, function and role in human diseases | Q29616303 | ||
| Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma | Q30615908 | ||
| Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors | Q33697130 | ||
| Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. | Q33962243 | ||
| Novel therapies for metastatic castrate-resistant prostate cancer | Q34249263 | ||
| Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. | Q34363544 | ||
| Endocrine therapy plus zoledronic acid in premenopausal breast cancer. | Q34943802 | ||
| Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins | Q35264079 | ||
| Molecular pathogenesis of multiple myeloma and its premalignant precursor | Q36290238 | ||
| Emerging anti-cancer molecular mechanisms of aminobisphosphonates | Q36443019 | ||
| The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma | Q36709283 | ||
| First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial | Q36804951 | ||
| Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells | Q36907149 | ||
| HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway | Q37073682 | ||
| Signal integration by JNK and p38 MAPK pathways in cancer development | Q37560607 | ||
| Biochemical and molecular mechanisms of action of bisphosphonates. | Q37812800 | ||
| Pharmacokinetic evaluation of zoledronic acid. | Q37874629 | ||
| Pathways of chemotherapy resistance in castration-resistant prostate cancer. | Q37874853 | ||
| Effects of bone-targeted agents on cancer progression and mortality. | Q38023206 | ||
| Zoledronic acid significantly enhances radiation‑induced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling | Q39225762 | ||
| HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. | Q39527047 | ||
| Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid | Q39644602 | ||
| Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis | Q39779497 | ||
| Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed | Q39875582 | ||
| Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors | Q39976173 | ||
| Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro | Q40048123 | ||
| Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells | Q40079732 | ||
| Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells | Q40104946 | ||
| R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation | Q40189572 | ||
| Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. | Q40344869 | ||
| The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate | Q40645503 | ||
| EPN: a novel epithelial cell line derived from human prostate tissue | Q40730255 | ||
| Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs | Q40945233 | ||
| Breast-cancer adjuvant therapy with zoledronic acid | Q42620139 | ||
| A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. | Q43136243 | ||
| The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function | Q44343595 | ||
| Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer | Q44918129 | ||
| Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. | Q45258262 | ||
| Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. | Q46434787 | ||
| Geraniol attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative stress and inflammation in mouse skin: possible role of p38 MAP Kinase and NF-κB. | Q46588819 | ||
| Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results | Q87419544 | ||
| P921 | main subject | prostate cancer | Q181257 |
| zoledronic acid | Q218507 | ||
| multiple myeloma | Q467635 | ||
| P304 | page(s) | e878 | |
| P577 | publication date | 2013-10-24 | |
| P1433 | published in | Cell Death and Disease | Q2197222 |
| P1476 | title | Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways | |
| P478 | volume | 4 |
| Q54943211 | A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. |
| Q38727632 | Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy. |
| Q29248583 | Dual roles of extracellular signal-regulated kinase (ERK) in quinoline compound BPIQ-induced apoptosis and anti-migration of human non-small cell lung cancer cells |
| Q33755160 | Exploiting Epigenetic Alterations in Prostate Cancer |
| Q91996955 | Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation |
| Q38179039 | Management of bone disease in multiple myeloma |
| Q42790822 | Molecular mechanisms of suberoylanilide hydroxamic acid in the inhibition of TGF-β1-mediated canine corneal fibrosis |
| Q38645501 | Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. |
| Q38717135 | Oxidative stress and proteasome inhibitors in multiple myeloma |
| Q28540022 | Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83 |
| Q37692256 | Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells. |
| Q37190106 | Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. |
| Q34602263 | The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma |
| Q36946596 | Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. |
| Q36962776 | Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways |
Search more.